.Pharmacolibrary.Drugs.A_AlimentaryTractAndMetabolism.A10B_BloodGlucoseLoweringDrugsExclInsulins.A10BD11_MetforminAndLinagliptin.MetforminAndLinagliptin .Pharmacolibrary.Drugs.A_AlimentaryTractAndMetabolism.A10B_BloodGlucoseLoweringDrugsExclInsulins.A10BD11_MetforminAndLinagliptin.MetforminAndLinagliptin| name: | MetforminAndLinagliptin |
| ATC code: | A10BD11 | route: | oral |
| n-compartments | 1 |
Metformin and linagliptin is a fixed-dose oral antidiabetic combination therapy used in the management of type 2 diabetes mellitus. Metformin is a biguanide antihyperglycemic agent that decreases hepatic glucose production and increases insulin sensitivity, while linagliptin is a dipeptidyl peptidase-4 (DPP-4) inhibitor that increases incretin levels to stimulate insulin release and suppress glucagon. This combination is approved for use in adults with type 2 diabetes.
Pharmacokinetic parameters summarized for healthy adult volunteers after oral administration of a fixed-dose combination tablet (metformin/linagliptin).
Pichereau, S, et al., & Friedrich, C (2015). Relative bioavailability study of linagliptin/metformin tablets in healthy Chinese subjects. International journal of clinical pharmacology and therapeutics 53(7) 582–592. DOI:10.5414/CP202237 PUBMED:https://pubmed.ncbi.nlm.nih.gov/26073354